

FROM :

PHONE NO. :

Nov. 30 2004 01:47AM P1

Continuation Sheet (PTOL-324)

Application No. 10/688,757

Continuation of 4(e) Other: Status identifiers should be present after each claim number. Markings and/or underlining were not presented with amended claims.

Notice of Non-Compliant Amendment (37 CFR 1.121)		Application No. 10/888,757	Applicant(s) CHANG ET AL.
		Examiner Timothy Cole	ART UNIT 1700
<p align="center"><i>— The MAILING DATE of this communication appears on the cover sheet with the correspondence address —</i></p> <p>The amendment document filed on 26 November 2005 is considered non-compliant because it has failed to meet the requirements of 37 CFR 1.121. In order for the amendment document to be compliant, correction of the following item(s) is required.</p> <p>THE FOLLOWING MARKED (O) ITEM(S) CAUSE THE AMENDMENT DOCUMENT TO BE NON-COMPLIANT:</p> <p><input checked="" type="checkbox"/> 1. Amendments to the specification: <input type="checkbox"/> A. Amended paragraph(s) do not include markings. <input type="checkbox"/> B. New paragraph(s) should not be underlined. <input type="checkbox"/> C. Other _____.</p> <p><input type="checkbox"/> 2. Abstract: <input type="checkbox"/> A. Not presented on a separate sheet. 37 CFR 1.72. <input type="checkbox"/> B. Other _____.</p> <p><input type="checkbox"/> 3. Amendments to the drawings: <input type="checkbox"/> A. The drawings are not properly identified in the top margin as "Replacement Sheet," "New Sheet," or "Annotated Sheet" as required by 37 CFR 1.121(d). <input type="checkbox"/> B. The practice of submitting proposed drawing correction has been eliminated. Replacement drawings showing amended figures, without markings, in compliance with 37 CFR 1.84 are required. <input type="checkbox"/> C. Other _____.</p> <p><input checked="" type="checkbox"/> 4. Amendments to the claims: <input type="checkbox"/> A. The listing of claims does not include the text of all pending claims (including withdrawn claims). <input checked="" type="checkbox"/> B. The listing of claims does not include the text of all pending claims (including withdrawn claims). <input checked="" type="checkbox"/> C. Each claim has not been provided with the proper status identifier, and as such, the individual status of each claim cannot be identified. Note: the status of every claim must be indicated after each claim under bolded lettering, or the following status identifiers: (Continued), (Currently Amended), (Cancelled), (Previously presented), (New), (Not entered), (Withdrawn) and (Withdrawn-currently amended). <input type="checkbox"/> D. The claims of this amendment paper have not been presented in ascending numerical order. <input checked="" type="checkbox"/> E. Other: See Continuation Sheet.</p>			
<p>For further explanation of the amendment format required by 37 CFR 1.121, see MPEP § 714 and the USPTO website at http://www.uspto.gov/web/offices/pac/dapp/oipa/procandlic/citicorver.pdf.</p> <p>TIME PERIODS FOR FILING A REPLY TO THIS NOTICE:</p> <p>1. Applicant is given no new time period if the non-compliant amendment is an after-final amendment or an amendment filed after allowance. If applicant wishes to resubmit the non-compliant after-final amendment with corrections, the entire corrected amendment must be resubmitted within the time period set forth in the final Office action.</p> <p>2. Applicant is given one month, or thirty (30) days, whichever is longer, from the mail date of this notice to supply the drawings and/or statement of the non-compliant amendment in compliance with 37 CFR 1.121. If the non-compliant amendment is one of the following: a preliminary amendment, a non-final amendment (including a submission for a request for continued examination (RCE) under 37 CFR 1.114), a supplemental amendment filed within a suspension period under 37 CFR 1.103(a) or (c), and an amendment filed in response to a Quayle action.</p> <p>Extensions of time are available under 37 CFR 1.136(e) only if the non-compliant amendment is a non-final amendment or an amendment filed in response to a Quayle action.</p> <p>Failure to timely respond to this notice will result in: Abandonment of the application if the non-compliant amendment is a non-final amendment or an amendment filed in response to a Quayle action; or Non-entry of the amendment if the non-compliant amendment is a preliminary amendment or supplemental amendment.</p>			

U.S. Patent and Trademark Office
PTOL-324 (11-04)

Notice of Non-Compliant Amendment (37 CFR 1.121)

Part of Paper No. 112505

(571)272-0999

**UNITED STATES PATENT AND TRADEMARK OFFICE**

UNITED STATES DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
ADDRESS: 1401 L ST., NW, SUITE 1450
www.uspto.gov

APPLICATION NO. 10/888,757	FILING DATE 10/20/2003	FIRST NAMED INVENTOR Yu-As Chang, Ph.D.	ATTORNEY DOCKET NO. 1993	CONFIRMATION NO. 1993
7990 Yu-As Chang, Ph.D. 3631 Hamilton Street Irvine, CA 92614		TELEPHONE 1-800-787-2727	EXAMINER PECCUTO, KAREN LIB	
		E-MAIL YUAS@USPTO.GOV	ART UNIT 1710	PAPER NUMBER 1
DATE MAILED: 12/02/2005				

Please find below and/or attached an Office communication concerning this application or proceeding.

PTO-90C (Rev. 10/03)

femoro-femoral artery implant, femoral-popliteal artery implant, femoro-tibial artery implant, fibular artery implant, plantar artery implant, dorsalis-pedis artery implant, arterial-venous fistulae, and venous implant, etc.

7. (Currently Amended) The drugs of claim 6 can be anti-coagulant drugs, anti-cancer drugs, Vascular Endothelial Growth Factor (VEGF) and/or Platelet Derived Growth Factor (PDGF) which include, but not limited to heparin, Taxol, and wherein said angiogenesis factor is selected from the group consisting of VEGF, VEGF 2, bFGF, VEGF121, VEGF165, VEGF189, VEGF206, PDGF, PDAF, TGF-B, PDGF, PDWHP, etc.

8. (Currently Amended) The bio-compatible surface processed copolymers can covalently attached with cells from specific tissue or cell lines to create special biological effects, such as endothelium cells to reduce blood activation, and other unwanted or harmful biological activities.